In this issue:
- Comorbidities and mortality across adult-onset diabetes subgroups
- CV outcomes of semaglutide and tirzepatide for type 2 diabetes
- Screening and assessment of type 2 diabetes risk factors among Māori/Pacific youth
- Comparative GI safety of GLP-1 agonists and tirzepatide in type 2 diabetes
- Association of age at type 2 diabetes onset with progression
- Infection-related hospitalisation risk with SGLT-2 inhibitors
- Global burden of early-onset type 2 diabetes
- Achieving glycaemic, BP and lipid targets in type 2 diabetes
- Acute pancreatitis and biliary disease risk after incretin initiation
- Combining SGLT-2 inhibitors with GLP-1 agonists for type 2 diabetes
Please login below to download this issue (PDF)